Top news of the week: 27.10.2020.

#biopharma #biotechnology #biospace #lifesciences #pharmaceuticals #analysis #STEMCareers #STEM #Covid19 #biotechs

Career And Jobs

On Oct 21, 2020
@pharminews shared
PureTech Founded Entity Vor Biopharma Appoints Matthew R Patterson to its Board of Directors https://t.co/vOzmdXhj5g #news #pharma #pharmiweb
Open

PureTech Founded Entity Vor Biopharma Appoints Matthew R Patterson to its Board of Directors

PureTech Founded Entity Vor Biopharma Appoints Matthew R Patterson to its Board of Directors

PureTech Health plc PureTech Founded Entity Vor Biopharma Appoints Matthew R Patterson to its Board of Directors PureTech Health plc (LSE: PRTC) (“PureTech” or the ...

On Oct 23, 2020
@EMDSerono shared
To close out #MassSTEMWeek, our Chief Commercial Officer, Scott Filosi, shared how growing up in MA & building a #biopharma career underscored the value of educating children in #STEM. https://t.co/yQfFitJKQF #SeeYourselfInSTEM #STEMCareers
Open

Biotech in Mass: How My Home State Grew Up with Me, and Looking Ahead to the Future

Biotech in Mass: How My Home State Grew Up with Me, and Looking Ahead to the Future

There are certain truths you hold dear to your heart when you grow up in Massachusetts: “Wicked” is an integral part of your vocabulary; there is nothing better than New England clam ...

On Oct 23, 2020
@JohnCendpts shared
Bain execs Adam Koppel and Jeffrey Schwartz line up $125M for their first blank check deal as Wall Street continues to embrace biotech https://t.co/X8f2LvWmSH
Open

Bain execs Adam Koppel and Jeffrey Schwartz line up $125M for their first blank check deal as Wall Street continues to embrace biotech

Bain execs Adam Koppel and Jeffrey Schwartz line up $125M for their first blank check deal as Wall Street continues to embrace biotech

Adam Koppel and Jeffrey Schwartz have jumped into the blank check game, raising $125 million for a stock listing in search of a company. Their SPAC, BCLS Acquisition Corp, raised $125 ...

On Oct 26, 2020
@Labiotech_eu shared
The #Covid19 pandemic has been accompanied by a surge of #cyberattacks in the life sciences industry, and the problem is likely to get far worse. In this #analysis, we explore why #biotechs need to brace themselves for the incoming wave. 💢 https://t.co/Io9ZCYOuhK #cybersecurity
Open

Biotech Startups Face a Growing Wave of Cyberattacks

Biotech Startups Face a Growing Wave of Cyberattacks

The Covid-19 pandemic has triggered a wave of cyberattacks in the life sciences industry this year, and the problem is likely to get worse. Biotech startups need to improve their ...

On Oct 22, 2020
@biospace shared
How the Biopharma Industry is Tackling the Opioid Crisis #biospace #lifesciences #biotechnology #pharmaceuticals #biopharma #opioid #opioidcrisis https://t.co/GKFnQ9WUK8
Open

How the Biopharma Industry is Tackling the Opioid Crisis

How the Biopharma Industry is Tackling the Opioid Crisis

Many drug makers are investing in new science and hope to transition pain therapy approaches away from synthetic opioids. Biospace has tracked a few key alternative therapeutic candidates.

On Oct 21, 2020
@JohnCendpts shared
Pfizer is on the verge of claiming a multibillion-dollar first-mover advantage with their Covid-19 vaccine — analyst $PFE https://t.co/cgfzo4dUZR
Open

Pfizer is on the verge of claiming a multibillion-dollar first-mover advantage with their Covid-19 vaccine — analyst

Pfizer is on the verge of claiming a multibillion-dollar first-mover advantage with their Covid-19 vaccine — analyst

From the beginning, Pfizer CEO Albert Bourla eschewed government funding for his Covid-19 vaccine work with BioNTech, willing to take all the $2 billion-plus risk of a lightning-fast ...

On Oct 22, 2020
@BioWorld shared
Be Biopharma launches with a $52M series A to develop engineered B-cell medicines https://t.co/a64BT2Qa38
Open

Be Biopharma launches with a $52M series A to develop engineered B-cell medicines

Be Biopharma launches with a $52M series A to develop engineered B-cell medicines

Be Biopharma Inc. is looking to develop engineered B cells to treat a wide range of diseases. The new category of cellular medicine is based on the work of David Rawlings and Richard James, ...

On Oct 22, 2020
@biospace shared
Be Biopharma, AavantiBio Launch With Millions in Financing to Support Therapeutic Goals #biospace #lifesciences #biotechnology #pharmaceuticals #Biopharma #AavantiBio https://t.co/ckb42IeCxd
Open

Be Biopharma, AavantiBio Launch With Millions in Financing to Support Therapeutic Goals

Be Biopharma, AavantiBio Launch With Millions in Financing to Support Therapeutic Goals

It’s a day of firsts, with the launch of two new Cambridge, Mass.-based life sciences companies.